zanubrutinib mantle cell
Selected indexed studies
- Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. (Blood, 2025) [PMID:39437708]
- Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review. (Blood Lymphat Cancer, 2023) [PMID:38034984]
- Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. (Blood, 2022) [PMID:35303070]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Zanubrutinib: past, present, and future. (2023) pubmed
- Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. (2025) pubmed
- Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review. (2023) pubmed
- Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. (2022) pubmed
- Zanubrutinib for mantle cell lymphoma, Waldenström's macroglobulinaemia. (2022) pubmed
- A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. (2021) pubmed
- Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. (2020) pubmed
- PMID:40834117 (2025) pubmed
- Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors. (2020) pubmed
- Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma. (2025) pubmed